September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Deciphering the molecular basis of periocular infiltrative basal cell carcinoma
Author Affiliations & Notes
  • John Bladen
    Centre for Cell Biology and Cutaneous Research, Blizard Institute, London, United Kingdom
  • Michèle Beaconsfield
    Moorfields Eye Hospital, London, United Kingdom
  • Edel O’Toole
    Centre for Cell Biology and Cutaneous Research, Blizard Institute, London, United Kingdom
  • Michael Philpott
    Centre for Cell Biology and Cutaneous Research, Blizard Institute, London, United Kingdom
  • Footnotes
    Commercial Relationships   John Bladen, None; Michèle Beaconsfield, None; Edel O’Toole, None; Michael Philpott, None
  • Footnotes
    Support  Fight For Sight UK
Investigative Ophthalmology & Visual Science September 2016, Vol.57, No Pagination Specified. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      John Bladen, Michèle Beaconsfield, Edel O’Toole, Michael Philpott; Deciphering the molecular basis of periocular infiltrative basal cell carcinoma. Invest. Ophthalmol. Vis. Sci. 201657(12):.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Basal cell carcinoma (BCC) is the commonest cancer worldwide and constitutes the vast majority of eyelid tumours. Infiltrative BCC (iBCC) is a particularly aggressive subtype, which invades local tissue and adjacent structures in an uncompromising manner. Little is known about the genetics of iBCC and the differences that render it more aggressive compared to the more benign nodular (nBCC) subtype

Methods : Fresh frozen tissue was collected from 20 BCC patients; 10 iBCC and 10 nBCC subtypes. Laser capture microdissection and nucleic acid extraction was performed. Whole exome sequencing of 20 BCC tumour and blood-matched controls were undertaken along with RNA sequencing of 3 iBCC and 3 nBCC tumour and stroma-matched controls. Differential expression (DE) from normal eyelid was deemed significant if P<0.01, Log2FC >1 or <-1. Quantitative RT-PCR and protein immunohistochemistry was performed for validation.

Results : For iBCC and nBCC, the average tumour mutational burden was 1533 and 2073, and UV signature was 88% and 85%, respectively. PTCH1 mutations were present in 80% of IBCC and 60% of nBCC. Novel iBCC driver included EPHA3 in 3 out of 10 patients. DE revealed 288 and 276 genes for iBCC and nBCC compared to normal, respectively. When both subtypes were compared, 128 genes were differentially expressed, with the majority upregulated in iBCC including LAMB3 and EPHB4. Shared genes included VCAN and GPC3. Immunohistochemistry confirmed Hedgehog (Hh) pathway expression, but to a much greater extent in iBCC including the surrounding non-tumour stromal tissue. Two key novel activated pathways were detected; axonal guidance and extracellular matrix (ECM) receptor interaction pathways.

Conclusions : Despite a reduced mutational burden in iBCC, the presence of significant driver mutations may explain its aggressive nature. Furthermore, the hyper-expression of the Hh pathway compared to nBCC including surrounding non-tumour stromal tissue may aid its local migration. Discovery of novel axonal guidance and ECM receptor interaction pathways could also play a role in this behaviour. Regardless of trends, the extent of tumour heterogeneity demands personalised genetic mapping of the tumour to direct developing novel treatment modalities such as inhibitors of EPHA3, VCAN, Gli1/2 and EPHB4.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×